Business

FivepHusion has announced the successful completion of the Phase 1 component of the Deflexifol at Relapse Trial, supported by the Kids with Cancer Foundation, an Australian-led study of a new brain cancer treatment for children.

Paradigm Biopharmaceuticals (ASX:PAR) has announced the acquisition of Proteobioactives, a company founded by Professor Peter Ghosh and based on his pioneering research into pentosan polysulfate sodium.

Firebrick Pharma (ASX:FRE) says it has secured commitments from qualifying investors for approximately $0.2 million through the issue of approximately 3.1 million new fully paid ordinary shares at an issue price of 6.3 cents per share.

Neuren Pharmaceuticals (ASX:NEU) has announced that the United States Patent and Trademark Office has allowed its patent application covering the use of NNZ-2591 to treat Pitt Hopkins syndrome.

Noxopharm (ASX:NOX) has announced that recruitment activities are progressing rapidly and on schedule for the HERACLES clinical trial.

QBiotics has announced the final efficacy and safety results from the first stage of its two-part Phase 2A clinical trial in patients with Soft Tissue Sarcoma, coinciding with Rare Cancers Awareness Day.

Amgen is partnering with the Australian Cancer Research Foundation with three initiatives to support women in cancer research following a survey that found 57 per cent of women in the sector reported facing gender discrimination.

Immutep (ASX:IMM) has announced positive initial efficacy data and continued favourable safety data from the placebo-controlled, double-blind first-in-human Phase 1 study evaluating IMP761, a first-in-class LAG-3 agonist antibody for autoimmune diseases.

Tryptamine Therapeutics (ASX:TYP) has received approval from the Swinburne University Human Research Ethics Committee to initiate a world-first clinical trial of TRP-8803 for adult patients with Binge Eating Disorder. 

Precision diagnostics company Proteomics International Laboratories (ASX:PIQ) has announced the successful development and release of the next generation of the PromarkerD test system.

AusBiotech has wrapped a significant week of bilateral and multilateral engagements at the BIO International Convention 2025 (BIO25) in Boston.

Amplia Therapeutics (ASX:ATX) has provided an update on the ongoing ACCENT trial investigating its FAK inhibitor narmafotinib in advanced pancreatic cancer.